Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese
  • Polish

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Are the microbiota and the gut-lung axis key factors in tuberculosis?
  • Our publications
    • News
    • HCP Magazine
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • Diagnosis tools
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Are the microbiota and the gut-lung axis key factors in tuberculosis?
Gastroenterology

Are the microbiota and the gut-lung axis key factors in tuberculosis?

Tuberculosis
Pulmonology Gastroenterology

The gut and lung microbiota may play an important role in the development of tuberculosis and in the effectiveness of treatment for the disease. So much so that probiotics and postbiotics may even be useful as an addition to current therapies or as drug optimization strategies.

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • HCP Magazine
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • Diagnosis tools
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

About this article

Created 11 February 2022
Updated 23 July 2024

(sidenote: Tuberculosis_WHO Oct 2021 ) (WHO, 2020), tuberculosis (TB) remains a major public health concern. This highly contagious infectious disease is caused by the bacterium Mycobacterium tuberculosis. According to a recent review, a number of studies have suggested the involvement of various microbiota.

Gut dysbiosis...

The gut microbiota is involved in the modulation of the host’s immune system. Studies have reported differences in gut microbiota composition between tuberculosis patients and healthy individuals, with specific intestinal signatures in TB patients (lower diversity, lower abundance of Bacteroides, etc.), which nevertheless vary according to the stage of the disease.

1.4 million people died from TB in 2019 (WHO, 2020).

Moreover, some studies on mouse models suggest that a gut dysbiosis may reduce the efficacy of antitubercular drugs. This implies that rebalancing the gut microbiota with probiotics or postbiotics may reinforce the efficacy of these drugs. It may also improve host immunity against the bacteria responsible for tuberculosis. The in vitro and in vivo anti-tuberculosis activity of probiotics and postbiotics is evidence of their potential.

... and lung dysbiosis

There are fewer studies on the lung microbiota. Conducted using bronchoalveolar lavage samples or sputum samples, they generally report a decrease in microbiota diversity in TB patients, with a change in the dominant species. These studies also suggest an important role for the lung microbiota in the development of tuberculosis and in the efficacy of treatment for the disease. This opens up the prospect of using certain respiratory commensal bacteria as new generation probiotics to treat resistant respiratory TB.

A gut-lung axis in TB

The gut and lung microbiota appear to be involved in the prevention, development, and treatment of tuberculosis. How? By affecting the number and function of immune cell subsets, by producing bacteriocins and bacteriolysins that restrict the growth of M. tuberculosis directly, and/or by influencing the bioavailability and pharmacokinetics of anti-TB drugs. Lastly, due to strong links between the gut microbiota and lung microbiota via a two-way dialogue, alterations in the former can affect the latter, and vice versa. Thus, by affecting host immune responses to M. tuberculosis, the gut-lung axis may play a key role in the prevention and treatment of TB.

Sources

Liu Y, Wang J, Wu C. Microbiota and Tuberculosis: A Potential Role of Probiotics, and Postbiotics. Front Nutr. 2021 May 7;8:626254.

Tags
Tuberculosis gut-lung axis Microbiome Flora
    Created 11 February 2022
    Updated 23 July 2024

    About this article

    To know more about this topic.

    Main topic

    Tuberculosis

    Medical practice

    Pulmonology Gastroenterology

    Content type

    News
    Gastroenterology

    Antimicrobial resistance fresco: learn, play and act now

    The Antimicrobial resistance fresco is an interactive and educational experience that raises awareness abou...

    Find out more

    Resilience of healthy adult gut microbiota following antibiotic exposure

    Commented articles - Adults' section By Pr. Harry Sokol ...

    Find out more

    Probiotics: what exactly are we talking about?

    From the Latin pro and Greek bios meaning “for life”, the term “probiotic” was suggested over 60 years ago,...

    Find out more

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial porti...

    Find out more

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irritable Bo...

    Find out more

    How do you choose a probiotic for your patient?

    Faced with a plethora of products on the market, it's not always easy for health professionals to suggest a...

    Find out more

    The Janus face of Antibiotics: Life Savers and Microbiota Disruptors

    A page turns: with the advent of antibiotics in the 20th century, this type of therapy, despite its undoubt...

    Find out more

    Fecal transplantation - ready for prime time?

    Congress review By Pr. Danny De Looze Department of Gastroenterology University Hospital Gent, Belgium ...

    Find out more

    Continue reading

    News
    30.10.2025

    Gut bacteria: natural traps for PFAS

    Read the article
    28.01.2025

    How to rebuild my gut microbiota after taking antibiotics?

    Read the article
    29.08.2023

    Massive amounts of antibiotic resistance genes found in clouds

    Read the article
    09.02.2022

    Antimicrobial resistance genes “stowaway” in gut microbiota during international travel

    Read the article
    08.01.2024

    When travel breeds antibiotic resistance

    Read the article
    08.03.2024

    Revolutionizing Infection Control: FMT's Role in Combatting Multidrug-Resistant Organisms in Transplant Patients

    Read the article
    Actu PRO : La transplantation fécale, solution à l’antibiorésistance chez les patients immunodéprimés ?
    14.05.2019

    Is fecal transplant a solution to prevent antibiotic resistance in immunocompromised patients?

    Read the article
    13.02.2024

    Antibiotics disrupt cancer immunotherapy via gut and immune effects

    Read the article
    • Our publications
      • News
      • HCP Magazine
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • Diagnosis tools
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español
    • Russian
    • Portuguese
    • Polish

    Browse the site

    • Our publications
      • News
      • HCP Magazine
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • Diagnosis tools
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "HCP Magazine" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    30.10.2025

    Gut bacteria: natural traps for PFAS

    Read the article
    15.10.2025

    How a 7-strain consortium rebuilds the gut to defeat antibiotics resistant bacteria

    Read the article
    Photo HCPs: AMR page for the 2025 WAAW campaign
    08.10.2025

    Everything you need to know about antibiotics and antimicrobial resistance

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "HCP Magazine" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • HCP Magazine
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • Diagnosis tools
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo